Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4749251 | 0.84 | CNR1 (0.40) | CKS1BSKP1SKP2 | |
| SCHEMBL14545490 | 0.84 | CKS1B (0.48) | CKS1BSKP1SKP2MAP4K4SUV39H2 | |
| SCHEMBL14523456 | 0.83 | CNR1 (0.52) | CKS1BSKP1SKP2MAP4K4SUV39H2 | |
| SCHEMBL4690150 | 0.82 | CKS1B (0.48) | CKS1BSKP1SKP2MAP4K4SUV39H2 | |
| SCHEMBL5516374 | 0.81 | CKS1B (0.63) | CKS1BSKP1SKP2GPR119RET | |
| SCHEMBL1580470 | 0.78 | CKS1B (0.52) | CKS1BSKP1SKP2MAP4K4SUV39H2 | |
| SCHEMBL1907903 | 0.78 | GPR119 (0.55) | CKS1BSKP1SKP2GPR119GBA1 | |
| SCHEMBL27027530 | 0.78 | MAP4K4 (0.55) | CKS1BSKP1SKP2MAP4K4SUV39H2 | |
| SCHEMBL22118550 | 0.76 | MAP4K4 (0.56) | CKS1BSKP1SKP2MAP4K4SUV39H2 | |
| SCHEMBL29435004 | 0.76 | MAP4K4 (0.56) | CKS1BSKP1SKP2MAP4K4SUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CKS1B 1836/4885SKP1 3576/4885SKP2 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.